|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 14/54 | (2006.01) |
| G01N2800/065 | (2013.01) | ||
| A61P 1/00 | (2006.01) | ||
| C07K 14/54 | (2013.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61P 1/04 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 1/16 | (2006.01) | ||
| A61P 1/18 | (2006.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 5/48 | (2006.01) | ||
| A61P 1/18 | (2018.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 11/02 | (2006.01) | ||
| A61P 11/02 | (2018.01) | ||
| A61P 11/06 | (2006.01) | ||
| A61P 11/06 | (2018.01) | ||
| A61P 15/14 | (2006.01) | ||
| A61P 15/14 | (2018.01) | ||
| A61P 17/06 | (2018.01) | ||
| A61P 17/06 | (2006.01) | ||
| A61P 19/02 | (2006.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 37/06 | (2006.01) | ||
| A61P 37/06 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61K 38/00 | (2006.01) | ||
| A61P 5/48 | (2018.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3169403 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15821351.2 |
| Date of filing the European patent application | 2015-07-15 | |
| (97) | Date of publication of the European application | 2017-05-24 |
| (45) | Date of publication and mention of the grant of the patent | 2024-02-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/040658 |
| Date | 2015-07-15 |
| (87) | Number | WO 2016/011208 |
| Date | 2016-01-21 |
| (30) | Number | Date | Country code |
| 201462025899 P | 2014-07-17 | US | |
| 201562119688 P | 2015-02-23 | US | |
| 201562119685 P | 2015-02-23 | US |
| (72) |
BOURNE, Gregory , AU
BHANDARI, Ashok , US
CHENG, XiaoLi , US
FREDERICK, Brian Troy , US
ZHANG, Jie , AU
PATEL, Dinesh V. , US
LIU, David , US
|
| (73) |
Protagonist Therapeutics, Inc. ,
7707 Gateway Boulevard, Suite 140, Newark, CA 94560-1160,
US
|
| (54) | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES |
| ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES |